No molecular similarity, only both are old. It is a prodrug of a modified nucleoside, just like remdesivir. Even the drug in Roche's pipeline is a modified nucleoside. The other difference is that we don't have 35 years of pharmacovigilance for them, like we have for Ivm.
Merck’s new drug shares molecular similarities to #Ivermectin. And why wouldn’t it? IVM is in a COVID-19 superstar lane all by itself and Merck, who held the patent until 1996, knows this.
It is criminal for the U.S. to pay Merck $1.2B when we already have the GOAT.https://twitter.com/sarf7a9z/status/1404441888233377793 …
-
-
Thanks. Twitter will use this to make your timeline better. UndoUndo
-
-
-
Does this mean prescription cost for ivermectin is about to be jacked up? Not good for horses and those of us with rosacea
Thanks. Twitter will use this to make your timeline better. UndoUndo
-
-
-
What will this do to the EUA for the vaccines? If there is now an acceptable treatment.
Thanks. Twitter will use this to make your timeline better. UndoUndo
-
-
-
Where's a source I can share with smart friends skeptical of repurposed drugs?
New conversation -
-
-
Interesting! This statement pretty much says it all...“Typically, when you evergreen something, you are not looking at any significant therapeutic advantage. You are looking at a company’s economic advantage.”
End of conversation
New conversation -
-
Um, Quantitative Structure-Activity Relationship/Quantitative Structure-Property Relationship is frequently used to make new drugs. Keep the good effects and try to change the bad, thus improving the medication's safety profile. This is propoganda like the rest of your stuff.
- Show replies
New conversation -
-
-
We've patented our new drug called Ivermuctan.
Thanks. Twitter will use this to make your timeline better. UndoUndo
-
Loading seems to be taking a while.
Twitter may be over capacity or experiencing a momentary hiccup. Try again or visit Twitter Status for more information.